---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018128"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:24:06.920718+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fennec real-world data show PEDMARK safe in adults with head & neck cancers, no disruption to cisplatin therapy

## Summary
- Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).
- PEDMARK given ≥6 hours after cisplatin was feasible and well tolerated; no grade 3/4 toxicities observed.
- Majority of high-risk patients had no measurable hearing loss during or after treatment despite baseline impairment.
- No disruption to curative-intent cisplatin-based treatment delivery was noted in the study.

## SEC filing metadata
- accession: 0001104659-26-018128
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/0001104659-26-018128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/fencf-20260220x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018128
- JSON: https://secwatch.observer/filing/0001104659-26-018128.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.